<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Transfusional <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001903'>anemias</z:hpo> can result in multiple organ failure </plain></SENT>
<SENT sid="1" pm="."><plain>Experience in the management of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> is limited, as many do not receive chelation therapy due to short-life expectancy and the difficulties associated with the administration of the current reference standard <z:chebi fb="0" ids="38161">chelator</z:chebi>, <z:chebi fb="0" ids="4356">deferoxamine</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>There have, however, been some reports of reduced transfusion requirement associated with chelation therapy in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we discuss a patient with primary <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> and related transfusion-dependent <z:hpo ids='HP_0001903'>anemia</z:hpo> who received chelation therapy with the once-daily oral iron <z:chebi fb="0" ids="38161">chelator</z:chebi>, <z:chebi fb="0" ids="49005">deferasirox</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>In addition to the reduced iron levels, the patient demonstrated an unexpected reduction in blood transfusion requirement, ultimately resulting in long-lasting transfusion-free survival </plain></SENT>
</text></document>